The daily business briefing: July 7, 2023

FDA grants full approval to Alzheimer's drug Leqembi, Yellen slams China for 'punitive' measures aimed at foreign firms, and more

Janet Yellen speaks in China
Janet Yellen is in Beijing to smooth relations between the U.S. and China
(Image credit: MARK SCHIEFELBEIN / POOL / AFP via Getty Images)

1. FDA grants full approval to Alzheimer's drug Leqembi

The Food and Drug Administration on Thursday gave full approval to Leqembi, a drug that can slow the progression of Alzheimer's disease. While other drugs have been approved that target the symptoms of Alzheimer's, this is the first time the FDA has granted full regulatory approval to one meant to slow cognitive decline. Leqembi, made by the drugmakers Eisai and Biogen, targets beta-amyloid, a kind of protein in the brain believed to play a role in Alzheimer's disease. For the phase 3 clinical trial of the drug, 1,795 people with mild cognitive impairment or early-stage Alzheimer's participated, and researchers found that over 18 months, progression of the disease slowed by 27%. This is not a cure, but "it's a first step for hopefully more therapeutics in the future," Dr. Ronald Peterson, a neurologist at the Mayo Clinic, told NBC News. Leqembi could cause serious side effects, including brain swelling and hemorrhage, and the drug will come with a boxed warning.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us